Many patients find that daily microdosing through drops produces a steadier experience with fewer GI disruptions
Insurance is not accepted per the brand's positioning
For targeted pigmentation issues, our High-Intensity Pico-Laser Therapy can offer remarkable results
Therapeutic peptides provide a concentrated, external dose that triggers a specific biological response
Read the full breakdown #MedicalAesthetics #AestheticPractitioner #GLP1 #BCAM #ClinicGovernance #IndemnityInsurance To view or add a comment, sign in Up to 65% of GLP-1 patients quit their program within a year
Emerging dual agonists, such as survodutide and cotadutide, which target GLP-1 and glucagon receptors, are being explored for treating metabolically associated fatty liver disease and may also address fatty kidney, a key factor in CKD related to visceral obesity [48]